CB Insights / patent data · Jan 2025
Clear Gene’s cancer-biomarker patent was shown as granted on Apr. 15, 2025, indicating continued IP development around residual breast cancer detection.
Our tests help eradicate cancer by telling doctors whether they got…
Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Clear Gene is a small biotechnology company focused on RNA diagnostics. Its website describes products for clinical labs, including rapid COVID-19 testing support and reagents/software to reduce or replace tedious RNA isolation workflows. Earlier company messaging also emphasized genomics and machine learning for detecting residual solid tumors.
Primary product
RNA diagnostics for clinical labs; rapid COVID-19 test support and related reagents/software
Founded
2012
Headquarters
San Carlos, California, United States
Team size
1-10 employees
Industry
Biotechnology
Sub-industry
RNA diagnostics / molecular diagnostics
Business model
Stage
seed
Total raised
$125K
Latest round
Seed · Dec 2018
Latest amount
$125K
Seed
Dec 2021
Pre Seed
Aug 2018
Leadership
Philip Shields
Director Of Logistics
Michael Janes
Research Director
Founders
Founder / CEO
Public company language emphasizes careful, methodical science, unorthodox ideas, and product development for frontline clinical labs.
Compensation
No public compensation data found. Limited public evidence suggests a small team with hiring activity historically, but no salary ranges were found.
Differentiators
Technology
Customers
Estimated monthly visits
1.7K
Traffic estimate as of May 2026
CB Insights / patent data · Jan 2025
Clear Gene’s cancer-biomarker patent was shown as granted on Apr. 15, 2025, indicating continued IP development around residual breast cancer detection.
LinkedIn · Feb 2022
LinkedIn post indicates hiring for research associates to support diagnostics development.
LinkedIn post by Brandon Steelman · Jun 2020
Brandon Steelman said Clear Gene was selected by the NIH RADx initiative to scale national COVID testing, a major validation/milestone during the pandemic.
Patent application record · Jun 2020
Patent application covering RNA/gene-expression-based analysis of residual disease and surgical-margin testing, reflecting the company’s core diagnostic platform.
37 jobs at Clear Gene